Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure
American Journal of Hematology · 07.11.2026
DOI: 10.1002/ajh.70542 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 07.11.2026. Verfasst von Atsushi Marumo und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Cleveland Clinic Foundation, Aplastic Anemia and MDS International Foundation, Edward P. Evans Foundation.
Abstract (Originalsprache)
BCOR and BCORL1 (BCOR/L1 ) mutations are observed in both myeloid neoplasms (MN) and bone marrow failure syndromes (BMF), but their clinical significance may differ. We analyzed 11 340 patients and identified 418 BCOR/L1 ‐mutated patients, focusing on differences between MN and BMF. Compared with MN, BMF was associated with younger age, a higher frequency of normal karyotype, a greater proportion of missense mutations, and significantly lower variant allele frequencies (VAFs). We next compared BCOR/L1 ‐mutated cases with wild‐type cases. In MN, BCOR/L1 mutations were associated with older age, inferior survival, and a higher number of co‐occurring mutations, whereas in BMF, they were associated with a higher prevalence of PNH clones. Single‐cell DNA sequencing and VAF‐based analysis demonstrated that BCOR/L1 mutations were usually secondary in MN but primary events in BMF. Longitudinal sequencing revealed that BCOR/L1 ‐mutant clones often contracted or disappeared over time, even in progression, suggesting limited clonal fitness of BCOR/L1 mutations themselves; instead, progression was associated with increased mutational burden, particularly in RUNX1 . Prognostically, BCOR/L1 mutations were associated with inferior survival in MN, whereas in BMF they were not associated with prognosis and tended to correlate with a favorable response to immunosuppressive therapy. RNA‐sequencing analyses showed reduced BCOR/L1 expression in BMF, and BCOR knockout was associated with reduced HLA class I expression. Our findings suggest that BCOR/L1 mutations are secondary events in MN and co‐occurring mutations may influence disease progression and prognosis, whereas in BMF they appear to be ancestral events acquired independently of progression to MN, potentially through immune privilege‐related mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Hematology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
- Hematology and Transplant Center, University Hospital "San Giovanni di Dio e Ruggi D'aragona", Salerno, Italy.
- Hematology, Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
- Department of Pediatric Hematology and Oncology Research, Research Institute, National Center for Child Health and Development, Tokyo, Japan.
- Fels Cancer Institute for Personalized Medicine, Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Atsushi Marumo, Aashray Mandala, Felipe de Almeida Sartori, Akram Abushamma, Serhan Unlu, Xiaorong Gu, Matteo D'Addona, Kartik Lakhotiya, Luca Guarnera, Masanori Yoshida, Monika M Toma, Mark D Orland, Carlos Bravo-Perez, Carmelo Gurnari, Koichi Takahashi, Tomasz Skorski, Stephan Hutter, Torsten Haferlach, Marcin Wlodarski, Valeria Visconte, Jaroslaw P Maciejewski
Förderung
- Cleveland Clinic Foundation
- Aplastic Anemia and MDS International Foundation
- Edward P. Evans Foundation
- Instituto de Salud Carlos III
- Nippon Medical School
- NCI NIH HHS
Zitieren
APA
Marumo, A., Durmaz, A., Haddad, C., Mandala, A., de Almeida Sartori, F., Abushamma, A., Unlu, S., Gu, X., Brady, Z., D'Addona, M., Lakhotiya, K., Guarnera, L., Yoshida, M., Toma, M. M., Orland, M. D., Bravo-Perez, C., Gurnari, C., Takahashi, K., Skorski, T., …, & Maciejewski, J. P. (2026). Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure. American Journal of Hematology. https://doi.org/10.1002/ajh.70542
Vancouver
Marumo A, Durmaz A, Haddad C, Mandala A, de Almeida Sartori F, Abushamma A, et al. Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure. American Journal of Hematology. 2026. doi:10.1002/ajh.70542
BibTeX
@article{Marumo2026,
author = {Marumo, Atsushi and Durmaz, Arda and Haddad, Christopher and Mandala, Aashray and de Almeida Sartori, Felipe and Abushamma, Akram and Unlu, Serhan and Gu, Xiaorong and Brady, Zachary and D'Addona, Matteo and Lakhotiya, Kartik and Guarnera, Luca and Yoshida, Masanori and Toma, Monika M and Orland, Mark D and Bravo-Perez, Carlos and Gurnari, Carmelo and Takahashi, Koichi and Skorski, Tomasz and Hutter, Stephan and Haferlach, Torsten and Wlodarski, Marcin and Visconte, Valeria and Maciejewski, Jaroslaw P},
title = {Distinct Consequences of BCOR and BCORL1 Mutations in Myeloid Neoplasms and Bone Marrow Failure},
journal = {American Journal of Hematology},
year = {2026},
doi = {10.1002/ajh.70542}
}
EUVIMED